- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00686296
Pilot Study Comparing Taliderm™ Dressing Versus Standard of Care for Open Incision and Drainage of Wounds
March 16, 2015 updated by: The University of Texas Health Science Center at San Antonio
To evaluate wound healing with the use of Taliderm™ dressing and compare it to wet to dry dressing in the treatment of open wounds after incision and drainage.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Inpatients with soft tissue abscess that will result in an open surgical wounds greater than or equal to 4 cms in any dimension
- Wound will require serial dressing changes
- Greater than or equal to 18 years of age
- Ability to obtain informed consent
Exclusion Criteria:
- Inability to obtain informed consent
- Pregnancy
- Prisoner
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group II
Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing.
Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit).
At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
|
taliderm™ dressing application once
Taliderm™ dressing application up to three applications
|
|
Other: III
standard wet to dry dressing with gauze
|
wet to dry dressing standard of care
|
|
Active Comparator: group I
Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
|
taliderm™ dressing application once
Taliderm™ dressing application up to three applications
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint of this study will be rate of wound healing (judged as per cent complete wound closure) at the two (2) and three (3) week follow-up visits.
Time Frame: two and three weeks
|
two and three weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
occurence of wound infection
Time Frame: two and three weeks
|
two and three weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: John G Myers, MD, The University of Texas Health Science Center at San Antonio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
May 26, 2008
First Submitted That Met QC Criteria
May 28, 2008
First Posted (Estimate)
May 29, 2008
Study Record Updates
Last Update Posted (Estimate)
March 17, 2015
Last Update Submitted That Met QC Criteria
March 16, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-2007-0709-H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds
-
Centre Hospitalier Universitaire de NīmesCompleted
-
National Center for Gastroentestinal and Liver...CompletedNeedlestick Injuries
-
Solventum US LLC3MWithdrawn
-
University of WashingtonU.S. Department of Justice; Arnold Ventures; City of SeattleCompleted
-
The First Affiliated Hospital of Xinxiang Medical...Recruiting
-
SerenaGroup, Inc.MDM Wound Ventures, LLCCompletedChronic Wounds | Acute WoundsUnited States
-
University of PittsburghThe Pittsburgh Foundation; Hillman Foundation; RK Mellon FoundationCompletedSkin Injury Due to Violence | Gunshot Wound, ContactUnited States
-
University of Mississippi Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD); National...Not yet recruiting
-
SerenaGroup, Inc.Anacapa Technologies IncCompleted
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
Clinical Trials on Taliderm™
-
Medical University of South CarolinaCompleted
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...Active, not recruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularCompletedAortic AneurysmGermany, United States, Netherlands, Switzerland, United Kingdom, New Zealand, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bKorea, Republic of
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis AGermany, Belgium, Czechia